Quinidine: Difference between revisions
(Created page with "==Background== *Inexpensive with restricted indications, causing it to be inaccessible in many areas globally *Main manufacturer halted production in 2010<ref>Olsson G.; To t...") |
No edit summary |
||
| Line 10: | Line 10: | ||
==Sources== | ==Sources== | ||
</ | <references/> | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
Revision as of 20:37, 5 August 2016
Background
- Inexpensive with restricted indications, causing it to be inaccessible in many areas globally
- Main manufacturer halted production in 2010[1]
- Historically both supraventricular tachydysrhytmia, ventricular dysrhythmia, malaria treatment, many other first-line therapies have replaced its use
- An effective treatment and prevention strategy for[2]:
- Brugada syndrome arrhythmic electrical storm
- Idiopathic ventricular fibrillation
- Early repolarization syndrome (though NOT benign, see benign early repolarization)
- Congenital short QT syndrome